Deals this week: Impact Therapeutics, Sienna Biopharmaceuticals, Advanced Proteome Therapeutics

10th August 2018 (Last Updated August 10th, 2018 00:00)

Impact Therapeutics has raised $30m through a series C financing round from Decheng Capital (Decheng).

Impact Therapeutics has raised $30m through a series C financing round from Decheng Capital (Decheng).

Existing investor Lilly Asian Ventures (LAV) also participated in the funding round.

Based in the US, Impact Therapeutics is a clinical-stage biopharmaceutical company engaged in the development and commercialisation of therapeutics for the treatment of cancer and other life-threatening diseases.

The company plans to use the funds towards clinical development and to advance its integrated programmes that target DNA Damage Response (DDR).

Sienna Biopharmaceuticals plans to raise $75m through a public offering of shares of its common stock.

Sienna has announced plans to raise $250m through a public offering of securities. The company intends to issue the securities periodically in any combination of common stock, preferred stock, and warrants.

Based in the US, Sienna specialises in the clinical development and commercialisation of products in aesthetics and dermatology.

The company plans to use the funds towards clinical development, working capital, and other general corporate purposes.

Latham & Watkins has been appointed as the legal adviser to the company for the offering.

"Sienna Biopharmaceuticals plans to raise $75m through a public offering of shares of its common stock."

Advanced Proteome Therapeutics has raised C$0.4m ($0.3m) through the private placement of eight million units priced at C$0.5 ($0.38) a unit.

Each unit consists of a common share and a transferable common share purchase warrant. Each full warrant is exercisable into one common share of the company at a price of C$0.075 ($0.057) a share for 24 months.

Based in the US, Advanced Proteome Therapeutics is a developer of novel therapeutics for cancer-causing tumours.

The company plans to use the funds towards the development of drug conjugates, research and development (R&D) activities, and for working capital.

Caladrius Biosciences has raised $25m through a public offering of shares.

Based in the US, Caladrius Biosciences is a clinical-stage biopharmaceutical company that develops regenerative medicines for cardiovascular diseases.

The company plans to use the funds towards research and development (R&D) activities, working capital, business expansion, and other general corporate purposes.

Mintz Levin Cohn Ferris Glovsky and Popeo, P.C. has been appointed as the legal adviser to the company for the offering.

Karuna Pharmaceuticals has raised $42m through a series A financing round from ARCH Venture Partners, the Wellcome Trust, Steven Paul M.D., and PureTech Health.

Based in the US, Karuna Pharmaceuticals is a clinical-stage pharmaceutical company engaged in targeting muscarinic receptors for the treatment of central nervous system (CNS) disorders.

The company plans to use the funds towards the development of its drug candidates and to support expansion into other therapeutic areas.